Descrizione del progetto
Solubilità sostenibile per l’industria farmaceutica e quella chimica
La misurazione della solubilità è un processo ad alta intensità di lavoro, sebbene necessario, che spesso richiede notevoli quantità di sostanze chimiche. I metodi attuali sono veloci ma imprecisi, oppure precisi ma lenti, e tutti richiedono un uso eccessivo di sostanze chimiche. Alla luce di tali premesse, il progetto FASS, finanziato dal CEI, offre all’industria farmaceutica e a quella chimica una soluzione sostenibile per affrontare queste sfide. Il progetto impiega lo scattering armonico secondo ad alta efficienza, combinando i vantaggi analitici delle attuali misure di solubilità con prestazioni rapide e accurate, sensibilità all’avanguardia e affidabilità. La soluzione concepita consente di limitare i costi del 90%, di accorciare i tempi di misurazione del 90%, di ridurre l’utilizzo di sostanze chimiche del 99%, di diminuire il consumo di elettricità del 97% e di tagliare il numero di composti utilizzati dell’80% rispetto allo standard di riferimento.
Obiettivo
Solubility measurement is a standard test that is required for every chemical that is produced or tested. However, measuring solubility is a time/labour-intensive process that requires substantial quantities of chemicals. State-of-the-Art solubility measurements are either fast but inaccurate or slow but accurate and require excess of chemicals. FASS is based on high-efficiency second harmonic scattering that combines the analytical advantages of current solubility measurements, fast and accurate, while achieving cutting edge performance in sensitivity and reliability. FASS saves 90% of cost, 90% of measurement time, 99% of chemicals and 97% of electricity and 80% of compounds compared to the gold standard. As an optical light scattering technique, FASS is non-destructive, and combined with analytical advantages and sustainable use of chemicals and compounds, provides a disruptive innovation in solubility measurement. The consortium is composed of a dedicated startup to bring the instrument to market, a research and technology organization to support technology maturation, a European Research Consortium to enable customer development and instrument demonstration and a center for pharmaceutical research to explore value-added applications of FASS in drug discovery and development. The goals of the project are: 1) to develop a demonstrator with optimized and robust performance suited for instrument demonstration and application exploration. 2) to validate the technology with early adopters in early stage drug discovery and development and chemical synthesis companies. 3) to develop a feasible business model and go-to-market strategy to be implemented by the startup. FASS brings a sustainable solution to the pharmaceutical and chemical industries, reduce chemical and electrical consumption, and through a dedicated startup, will create jobs, foster competition and contribute to the growth of the pharmaceutical industry and the European economy.
Parole chiave
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Invito a presentare proposte
(si apre in una nuova finestra) HORIZON-EIC-2023-TRANSITION-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-EIC - HORIZON EIC GrantsCoordinatore
13125 Berlin
Germania